国家肺癌筛查试验中胸部CT筛查参与者的肺外发现与恶性肿瘤
研究回顾性分析国家肺癌筛查试验(NLST)中17309名接受低剂量胸部CT筛查的参与者,肺外发现占58.7%,其中19.6%被编码为可能显著。可能显著异常以心血管发现患病率最高(8.5%),筛查期间诊断肺外原发恶性肿瘤67例(0.39%)。作者认为对肺外偶发发现不加区分地检查可能给医疗系统带来负担而获益有限,放射科医生应熟悉ACR白皮书关于偶发发现的现有建议。
要点
- 胸部CT筛查参与者中58.7%存在肺外发现,19.6%被编码为可能显著。
- 可能显著异常患病率:心血管8.5%、肾脏2.4%、肝胆2.1%、肾上腺1.2%、甲状腺0.6%。
- 筛查期间诊断肺外原发恶性肿瘤67/17309例(0.39%),肾癌0.26%、甲状腺癌0.08%、肝癌0.05%。
核心结论
- 约五分之一的肺癌CT筛查者存在可能需进一步评估的肺外发现;筛查期间诊断的肺外恶性肿瘤不常见,对偶发肺外发现不加区分地检查可能给医疗系统带来显著负担而获益有限;放射科医生报告筛查CT时应熟悉ACR白皮书关于偶发发现的现有建议。
研究设计与样本
- 对NLST中2002年8月至2007年9月接受低剂量筛查胸部CT的17309名参与者前瞻性采集的数据进行回顾性分析,NLST放射科读片者将肺外发现编码为「轻微」或「可能显著」,依据记录的文字描述归入心血管、甲状腺、肾上腺、肾脏和肝胆五个器官分组,并从医疗和生命状态记录中识别筛查期间诊断的肺外恶性肿瘤,计算各器官特异性发现及新诊断肺外恶性肿瘤的患病率,研究获人体受试者研究审查豁免。
诊断标准与关键数值
- 肺外发现总患病率58.7%,其中编码为可能显著的占19.6%。
- 可能显著异常患病率:心血管8.5%、肾脏2.4%、肝胆2.1%、肾上腺1.2%、甲状腺0.6%。
- 筛查期间诊断肺外原发恶性肿瘤67/17309例(0.39%),其中肾癌0.26%(n=45)、甲状腺癌0.08%(n=14)、肝癌0.05%(n=8)。
临床应用与阅片要点
- 放射科医生报告筛查CT时应熟悉ACR白皮书关于偶发发现的现有建议。
- 对肺外偶发发现不加区分地检查可能给医疗系统带来显著负担而获益有限,因为筛查期间诊断的肺外恶性肿瘤不常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to measure the prevalence of clinically significant extrapulmonary findings on chest CT for lung cancer screening in the National Lung Screening Trial (NLST).
METHODS: Prospectively acquired data on 17,309 participants who underwent low-dose screening chest CT from August 2002 through September 2007 during the NLST were retrospectively analyzed for extrapulmonary findings. NLST radiologist readers coded such findings as "minor" or "potentially significant." On the basis of review of recorded text descriptions, extrapulmonary findings were assigned to five organ groupings (cardiovascular, thyroid, adrenal, renal, and hepatobiliary). Extrapulmonary malignancies diagnosed during screening were also identified from medical and vital status records in the same population. The prevalence rates of organ-specific findings and newly diagnosed extrapulmonary malignancies were calculated. Exemption from human subjects research review was obtained.
RESULTS: Extrapulmonary findings were noted in 58.7% of CT-screened participants, and 19.6% had findings coded as potentially significant. The prevalence of potentially significant abnormalities was highest for cardiovascular findings (8.5%), followed by renal (2.4%), hepatobiliary (2.1%), adrenal (1.2%), and thyroid (0.6%) findings. Sixty-seven of 17,309 participants (0.39%) had primary extrathoracic cancers diagnosed during screening. The prevalence of cancers among screened participants was 0.26% (n = 45) for kidney, 0.08% (n = 14) for thyroid, and 0.05% (n = 8) for liver cancers.
CONCLUSIONS: One in five patients screened with CT for lung cancer will have extrapulmonary findings potentially requiring further evaluation. Indiscriminate workups of incidental extrapulmonary findings could place a significant burden on the health care system with little benefit because extrapulmonary malignancies diagnosed during screening are uncommon. Radiologists reporting screening CT should be familiar with existing recommendations for incidental findings from the ACR white papers.
引用
- Nguyen XV, Davies L, Eastwood JD, et al. Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial. J Am Coll Radiol. 2017. PMID: 28259326. doi:10.1016/j.jacr.2016.09.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。